← 產業報告目錄

Pharmaceutical Quality Management Software (QMS) Market by Process (Clinical Trial, Regulatory, Manufacturing, Commercialization), Application (eSOP, CAPA, Compliance), Size (Large, Small), End User (pharma, biotech, CRO), Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-11-17頁數 302報告編號 HIT9540

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global pharmaceutical QMS market is projected to reach USD 2.98 billion by 2030 from USD 1.59 billion in 2025, at a CAGR of 13.3% during the forecast period. The pharmaceutical QMS market is experiencing consistent growth, driven by increasing regulatory requirements, the need for streamlined compliance processes, and rising demand for digital transformation in the pharmaceutical industry. Companies are adopting QMS solutions to improve efficiency, minimize errors, and ensure compliance with global standards such as FDA, EMA, and ISO guidelines. Additionally, the increasing complexity of drug development, clinical trials, and manufacturing operations is further boosting adoption. This trend reflects the industry’s move toward integrated, automated, and data-driven quality management systems to enhance overall product quality, patient safety, and accelerate time-to-market efficiency. “Regulatory compliance under the process segment is expected to register the fastest growth rate during the forecast period.” By process, the regulatory compliance segment is expected to grow the fastest in the pharmaceutical QMS market. This expansion is driven by the growing complexity of global regulatory requirements and the increasing need for pharmaceutical companies to meet stringent quality and safety standards set by agencies such as the FDA, EMA, and WHO. QMS helps organizations efficiently manage audits, documentation, and reporting tasks, thereby reducing the risk of non-compliance and associated penalties. Moreover, the rising demand for automated compliance tracking, real-time data visibility, and centralized document control is boosting the adoption of QMS solutions across the industry. “CAPA management under the application segment is expected to be the fastest-growing segment during the forecast period.” By application, the CAPA (Corrective and Preventive Action) management segment is expected to be the fastest-growing area in the pharmaceutical QMS market. This growth is fueled by the rising focus on proactively identifying and fixing quality issues to meet regulatory standards. CAPA solutions help pharmaceutical companies systematically investigate root causes, implement corrective actions, and prevent the recurrence of deviations or nonconformities. The increasing integration of automation, data analytics, and real-time monitoring within CAPA processes further boosts efficiency and accuracy. As companies aim to maintain high-quality standards and reduce operational risks, the demand for advanced CAPA capabilities within QMS platforms continues to grow rapidly. “The Asia Pacific is expected to witness the highest growth rate during the forecast period.” The Asia Pacific is expected to experience the fastest growth in the pharmaceutical QMS market, driven by the rapid expansion of pharmaceutical manufacturing capacities, an increasing number of clinical trials outsourced to the region, and greater regulatory alignment with global standards. Additionally, the rise in digitization efforts, combined with investments in advanced IT infrastructure and automation for compliance, is fueling widespread adoption of integrated QMS platforms to improve quality assurance, simplify documentation, and maintain regulatory compliance across complex, multi-site operations. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace. The breakdown of primary participants is as mentioned below: • By Company Type - Tier 1: 31%, Tier 2: 28%, and Tier 3: 41% • By Designation - C-level: 31%, Director-level: 25%, and Others: 44% • By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5% Key Players in the Pharmaceutical QMS Market The key players operating in the Pharmaceutical QMS market include Veeva Systems Inc. (US), MasterControl Solutions, Inc. (US), Honeywell International Inc. (US), IQVIA (US), Qualio, Inc. (US), Hexagon AB (Sweden), AssurX, Inc. (US), QT9 Software (US), Dassault Systèmes (France), ComplianceQuest (US), Ideagen (UK), SoftExpert (Brazil), Xybion Digital Inc. (US), Intelex Technologies (Canada), Intellect, Inc. (US), AmpleLogic (India). Research Coverage: The report analyzes the pharmaceutical QMS market and aims to estimate its size and future growth potential across various segments based on process, application, enterprise size, end user, and region. It also provides a competitive analysis of the key players in the market, along with their company profiles, product offerings, recent developments, and key market insights strategies. Reasons to Buy the Report This report will help both established firms and newer or smaller companies understand the market trends, which can assist them in gaining a larger share of the market. Companies using the report can apply one or a combination of the strategies listed below to strengthen their positions in the market. This report provides insights into:  Analysis of key drivers (stringent regulatory compliance pressures are pushing pharma companies to adopt QMS solutions, Globalization of pharmaceutical operations is driving the need for digitalization and automation of QMS systems, cost pressures, reduce errors, and the need for operational efficiency in pharma, Increasing emphasis on risk management and adherence to regulatory standards), restraints (reluctance to adapt to new software solutions, strict data protection laws (GDPR, HIPAA) raise cybersecurity costs and slow software adoption, Concerns regarding data security & privacy), opportunities (increasing demand for specialized cloud-based software solutions in pharma manufacturing, Rising number of small & mid-sized pharma companies to propel market growth, expansion across emerging regions, fuelled by rising pharmaceutical manufacturing activities and evolving regulatory frameworks, adoption of AI and analytics to enable proactive quality management), and challenges (high initial costs of pharma QMS solutions, Variability in regulatory standards across regions, Shortages of skilled R&D and quality professionals with expertise in AI and advanced digital platforms) influencing the growth of the pharmaceutical QMS market.  Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the pharmaceutical QMS market.  Market Development: Comprehensive information on the lucrative emerging markets, application, process, enterprise size, end user, and region.  Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the pharmaceutical QMS market  Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the pharmaceutical QMS market, like Veeva Systems, Inc. (US), MasterControl Solutions, Inc. (US), Honeywell International Inc. (US), IQVIA (US), and Dassault Systèmes (France).
目錄 Table of Contents
1 INTRODUCTION 28 1.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 MARKET SCOPE 29 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 29 1.3.2 INCLUSIONS AND EXCLUSIONS 30 1.3.3 YEARS CONSIDERED 31 1.4 CURRENCY CONSIDERED 31 1.5 STAKEHOLDERS 32 2 EXECUTIVE SUMMARY 33 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 33 2.2 KEY MARKET PARTICIPANTS: INSIGHTS AND STRATEGIC DEVELOPMENTS 34 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 35 2.4 HIGH-GROWTH SEGMENTS & EMRGING FRONTIERS 36 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 37 3 PREMIUM INSIGHTS 38 3.1 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET OVERVIEW 38 3.2 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE & REGION 39 3.3 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: GEOGRAPHIC SNAPSHOT 40 3.4 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS 41 4 MARKET OVERVIEW 42 4.1 INTRODUCTION 42 4.2 MARKET DYNAMICS 42 4.2.1 DRIVERS 43 4.2.1.1 Stringent regulatory compliance 43 4.2.1.2 Globalization of pharmaceutical operations 44 4.2.1.3 Growing demand for operational efficiency and reduce human errors 45 4.2.1.4 Increasing emphasis on risk management and adherence to regulatory standards 45 4.2.2 RESTRAINTS 46 4.2.2.1 Reluctance to adopt new software solutions 46 4.2.2.2 Strict data protection laws 46 4.2.2.3 Data security and privacy concerns 47   4.2.3 OPPORTUNITIES 47 4.2.3.1 Increasing demand for specialized cloud-based software solutions 47 4.2.3.2 Rising number of small & mid-sized pharma companies 48 4.2.3.3 Expanding pharmaceutical industry in emerging regions 49 4.2.3.4 Adoption of AI and advanced analytics 49 4.2.4 CHALLENGES 50 4.2.4.1 High initial costs of implementing quality management systems 50 4.2.4.2 Variability in regulatory standards 50 4.2.4.3 Shortage of skilled R&D and quality professionals 51 4.3 UNMET NEEDS AND WHITE SPACES 51 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 51 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 52 5 INDUSTRY TRENDS 53 5.1 PORTER’S FIVE FORCES ANALYSIS 53 5.1.1 THREAT OF SUBSTITUTES 54 5.1.2 THREAT OF NEW ENTRANTS 54 5.1.3 BARGAINING POWER OF BUYERS 54 5.1.4 BARGAINING POWER OF SUPPLIERS 54 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 54 5.2 MACROECONOMIC OUTLOOK 55 5.2.1 INTRODUCTION 55 5.2.2 GDP TRENDS AND FORECAST 55 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 56 5.3 VALUE CHAIN ANALYSIS 57 5.4 ECOSYSTEM ANALYSIS 59 5.5 PRICING ANALYSIS 61 5.5.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024 61 5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2024 62 5.6 KEY CONFERENCES AND EVENTS, 2025–2026 62 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS 64 5.8 INVESTMENT AND FUNDING SCENARIO 65 5.9 CASE STUDY ANALYSIS 65 5.10 IMPACT OF 2025 US TARIFF 66 5.10.1 INTRODUCTION 66 5.10.2 KEY TARIFF RATES 67 5.10.3 PRICE IMPACT ANALYSIS 67 5.10.4 IMPACT ON COUNTRY/REGION 68 5.10.4.1 US 68 5.10.4.2 Europe 68 5.10.4.3 Asia Pacific 68   5.10.5 IMPACT ON END-USE INDUSTRIES 68 5.10.5.1 Pharmaceutical companies 68 5.10.5.2 Biotechnology companies 69 5.10.5.3 Contract Research Organizations (CROs) 69 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 70 6.1 KEY EMERGING TECHNOLOGIES 70 6.1.1 GENERATIVE AI & MACHINE LEARNING 70 6.1.2 CLOUD COMPUTING & SAAS PLATFORMS 70 6.1.3 ROBOTIC PROCESS AUTOMATION 70 6.2 COMPLEMENTARY TECHNOLOGIES 71 6.2.1 MANUFACTURING EXECUTION SYSTEMS (MES) 71 6.2.2 ENTERPRISE RESOURCE PLANNING (ERP) SYSTEMS 71 6.2.3 ELECTRONIC DATA MANAGEMENT SYSTEMS (EDMS) 71 6.3 TECHNOLOGY/PRODUCT ROADMAP 72 6.4 PATENT ANALYSIS 72 6.4.1 JURISDICTION ANALYSIS 72 6.4.2 MAJOR PATENTS 74 6.4.3 LIST OF PATENTS 74 6.5 FUTURE APPLICATIONS 76 6.5.1 AUTOMATED AUDIT AND INSPECTION 76 6.5.2 AI-POWERED COMPLIANCE MONITORING 76 6.5.3 ADVANCED ANALYTICS DASHBOARDS 76 6.5.4 MOBILE QMS APPLICATIONS 76 6.5.5 SUPPLIER QUALITY MANAGEMENT AUTOMATION 77 6.6 IMPACT OF AI/GEN AI ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET 77 6.6.1 INTRODUCTION 77 6.6.2 MARKET POTENTIAL OF AI/GEN AI IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET 78 6.6.3 CASE STUDY RELATED TO AI/GEN AI IMPLEMENTATION 80 6.6.3.1 Use of unified QMS platform for quality documentation 80 6.6.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 81 6.6.4.1 Automated audit simulation 81 6.6.4.2 Real-time monitoring & alerts 81 6.6.4.3 Regulatory & compliance services 82 6.6.4.4 Research laboratories & contract manufacturers 82 6.6.5 USER READINESS AND IMPACT ASSESSMENT 82 6.6.5.1 User readiness 82 6.6.5.1.1 User A: Pharmaceutical companies 82 6.6.5.1.2 User B: Biotechnology companies 82 6.6.5.2 Impact assessment 83 6.6.5.2.1 User A: Pharmaceutical companies 83 6.6.5.2.1.1 Implementation 83 6.6.5.2.1.2 Impact 83 6.6.5.2.2 User B: Biotechnology companies 83 6.6.5.2.2.1 Implementation 83 6.6.5.2.2.2 Impact 83 7 REGULATORY LANDSCAPE 84 7.1 REGIONAL REGULATIONS AND COMPLIANCE 84 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 7.1.2 INDUSTRY STANDARDS 88 7.1.2.1 North America 88 7.1.2.2 Europe 88 7.1.2.3 Asia Pacific 89 7.1.2.4 Middle East & Africa 90 7.1.2.5 Latin America 90 8 CUSTOMER LANDSCAPE & BUYING BEHAVIOUR 91 8.1 DECISION-MAKING PROCESS 91 8.2 BUYERS STAKEHOLDERS AND BUYING EVALUATION CRITERIA 91 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 91 8.2.2 KEY BUYING CRITERIA 92 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 93 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 93 9 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS 94 9.1 INTRODUCTION 95 9.2 CLINICAL TRIALS 95 9.2.1 NEED TO ENSURE CLINICAL EXCELLENCE AND REGULATORY INTEGRITY TO EXPEDITE GROWTH 95 9.3 REGULATORY COMPLIANCE 96 9.3.1 INCREASING EMPHASIS ON COMPLYING WITH STRINGENT INTERNATIONAL STANDARDS TO AID GROWTH 96 9.4 MANUFACTURING/PRODUCTION 97 9.4.1 GROWING FOCUS ON CONSISTENT PRODUCT QUALITY TO DRIVE MARKET 97 9.5 QUALITY ASSURANCE/QUALITY CONTROL 98 9.5.1 INCREASING FOCUS ON CONTINUOUS MONITORING, DOCUMENTATION, AND CONTROL IN PHARMA PRODUCTION TO FAVOR GROWTH 98 9.6 DISTRIBUTION & SUPPLY CHAIN 99 9.6.1 COMPLEX GLOBAL SUPPLY NETWORKS TO CONTRIBUTE TO GROWTH 99 9.7 COMMERCIALIZATION, MARKETING, AND SALES 100 9.7.1 RISING INTRODUCTION OF COMPLEX THERAPIES AND EVOLVING REGULATIONS TO SUSTAIN GROWTH 100 9.8 POST-MARKET SURVEILLANCE 101 9.8.1 GROWING FOCUS ON PRODUCT PERFORMANCE AND PATIENT SAFETY TO BOOST MARKET 101 9.9 OTHER PROCESSES 102 10 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION 104 10.1 INTRODUCTION 105 10.2 DOCUMENT CONTROL & ESOP 105 10.2.1 NEED TO MANAGE AND CONTROL CRITICAL QUALITY DOCUMENTS TO FACILITATE GROWTH 105 10.3 CAPA (CORRECTIVE AND PREVENTIVE ACTION) MANAGEMENT 106 10.3.1 ABILITY TO ADDRESS DETECTION, RESOLUTION, AND PREVENTION OF QUALITY AND COMPLIANCE ISSUES TO FUEL MARKET 106 10.4 AUDIT & INSPECTION MANAGEMENT 107 10.4.1 INCREASING FOCUS ON EFFECTIVE AUDIT AND INSPECTION MANAGEMENT TO BOLSTER GROWTH 107 10.5 TRAINING MANAGEMENT 108 10.5.1 RISING AUTOMATION AND STANDARDIZATION IN TRAINING ACTIVITIES TO ADVANCE GROWTH 108 10.6 REGULATORY & COMPLIANCE MANAGEMENT 109 10.6.1 EVOLVING GLOBAL REGULATORY REQUIREMENTS TO ACCELERATE GROWTH 109 10.7 SUPPLIER QUALITY MANAGEMENT 110 10.7.1 NEED TO MAINTAIN SUPPLIER RELIABILITY, MATERIAL INTEGRITY, AND REGULATORY COMPLIANCE TO SPUR GROWTH 110 10.8 RISK MANAGEMENT 111 10.8.1 COMPLEX NATURE OF PHARMACEUTICAL OPERATIONS TO ENCOURAGE GROWTH 111 10.9 CHANGE CONTROL MANAGEMENT 112 10.9.1 RISING TRANSITION TOWARD DIGITAL SYSTEMS TO STIMULATE GROWTH 112 10.10 OTHER APPLICATIONS 113 11 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE 115 11.1 INTRODUCTION 116 11.2 LARGE ENTERPRISES 116 11.2.1 RISING DIGITAL TRANSFORMATION AND COMPLIANCE MODERNIZATION STRATEGIES TO EXPEDITE GROWTH 116 11.3 SMALL & MEDIUM ENTERPRISES 117 11.3.1 INCREASING ADOPTION OF CLOUD-BASED, MODULAR, AND SCALABLE QMS SOLUTIONS TO AID GROWTH 117 12 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER 119 12.1 INTRODUCTION 120 12.2 PHARMACEUTICAL COMPANIES 120 12.2.1 INCREASING INVESTMENTS IN AI AND ANALYTICS-ENABLED QMS PLATFORMS TO PROPEL MARKET 120 12.3 BIOTECHNOLOGY COMPANIES 121 12.3.1 STRONG FOCUS ON INNOVATION, REGULATORY COMPLIANCE, AND MANUFACTURING PRECISION TO FAVOR GROWTH 121 12.4 CONTRACT RESEARCH ORGANIZATIONS 122 12.4.1 INCREASING CLINICAL RESEARCH, DATA MANAGEMENT, AND REGULATORY SUBMISSION ACTIVITIES TO SUSTAIN GROWTH 122 12.5 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 123 12.5.1 CRUCIAL ROLE IN GLOBAL DRUG PRODUCTION, FORMULATION DEVELOPMENT, AND SUPPLY CHAIN MANAGEMENT TO DRIVE MARKET 123 12.6 OTHER END USERS 124 13 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY REGION 126 13.1 INTRODUCTION 127 13.2 NORTH AMERICA 128 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 128 13.2.2 US 131 13.2.2.1 Growing need for operational excellence in life sciences sector to boost market 131 13.2.3 CANADA 134 13.2.3.1 Increasing digital transformation initiatives and focus on lifecycle quality management to aid growth 134 13.3 EUROPE 137 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 137 13.3.2 GERMANY 140 13.3.2.1 Robust pharma infrastructure to propel market 140 13.3.3 UK 142 13.3.3.1 Increasing focus on comprehensive patient safety and risk management solutions to spur growth 142 13.3.4 FRANCE 145 13.3.4.1 Strict regulatory environment to foster growth 145 13.3.5 ITALY 147 13.3.5.1 Rising compliance mandates to contribute to growth 147 13.3.6 SPAIN 150 13.3.6.1 Need for scalable, cost-effective, and regulatory-ready systems to augment growth 150 13.3.7 REST OF EUROPE 152   13.4 ASIA PACIFIC 155 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 155 13.4.2 CHINA 158 13.4.2.1 Rising clinical & manufacturing volumes and growing number of biotech companies to drive market 158 13.4.3 JAPAN 161 13.4.3.1 Increasing adoption of cloud systems and electronic records to aid growth 161 13.4.4 INDIA 164 13.4.4.1 Expanding pharmaceutical manufacturing base and increasing regulatory scrutiny from global health authorities to drive market 164 13.4.5 AUSTRALIA 166 13.4.5.1 Increasing shift toward electronic integrated quality ecosystems to promote growth 166 13.4.6 SOUTH KOREA 169 13.4.6.1 Growing focus on lifecycle quality management to propel market 169 13.4.7 REST OF ASIA PACIFIC 171 13.5 LATIN AMERICA 174 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 174 13.5.2 BRAZIL 177 13.5.2.1 Growing investments in automated quality systems to drive market 177 13.5.3 MEXICO 179 13.5.3.1 Increasing emphasis on data integrity and electronic documentation to boost market 179 13.5.4 REST OF LATIN AMERICA 181 13.6 MIDDLE EAST & AFRICA 184 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 184 13.6.2 GCC COUNTRIES 186 13.6.2.1 Saudi Arabia 189 13.6.2.1.1 Increasing local manufacturing and enhanced regulatory compliance to promote growth 189 13.6.2.2 UAE 192 13.6.2.2.1 Rising regulatory modernization and national manufacturing initiatives to sustain growth 192 13.6.2.3 Rest of GCC countries 194 13.6.3 SOUTH AFRICA 197 13.6.3.1 Evolving regulatory expectations and digitalization trends to fuel market 197 13.6.4 REST OF MIDDLE EAST & AFRICA 199   14 COMPETITIVE LANDSCAPE 202 14.1 OVERVIEW 202 14.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN 202 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 203 14.3 REVENUE SHARE ANALYSIS 204 14.4 MARKET SHARE ANALYSIS 205 14.5 SOFTWARE COMPARISON 208 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 209 14.6.1 STARS 209 14.6.2 EMERGING LEADERS 209 14.6.3 PERVASIVE PLAYERS 209 14.6.4 PARTICIPANTS 209 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 211 14.6.5.1 Company footprint 211 14.6.5.2 Region footprint 212 14.6.5.3 Process footprint 213 14.6.5.4 Application footprint 214 14.6.5.5 Enterprise size footprint 215 14.6.5.6 End-user footprint 216 14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 217 14.7.1 PROGRESSIVE COMPANIES 217 14.7.2 RESPONSIVE COMPANIES 217 14.7.3 DYNAMIC COMPANIES 217 14.7.4 STARTING BLOCKS 217 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 219 14.7.5.1 Detailed list of key startups/SMEs 219 14.7.5.2 Competitive benchmarking of key startups/SMEs 220 14.8 COMPANY VALUATION AND FINANCIAL METRICS 221 14.8.1 COMPANY VALUATION 221 14.8.2 FINANCIAL METRICS 221 14.9 COMPETITIVE SCENARIO 222 14.9.1 PRODUCT LAUNCHES AND APPROVALS 222 14.9.2 DEALS 223 14.9.3 EXPANSIONS 224 14.9.4 OTHER DEVELOPMENTS 224   15 COMPANY PROFILES 225 15.1 KEY PLAYERS 225 15.1.1 HONEYWELL INTERNATIONAL INC. 225 15.1.1.1 Business overview 225 15.1.1.2 Products offered 226 15.1.1.3 Recent developments 227 15.1.1.3.1 Product launches and approvals 227 15.1.1.3.2 Deals 228 15.1.1.4 MnM view 228 15.1.1.4.1 Key strengths/Right to win 228 15.1.1.4.2 Strategic choices 228 15.1.1.4.3 Weaknesses/Competitive threats 228 15.1.2 IQVIA 229 15.1.2.1 Business overview 229 15.1.2.2 Products offered 230 15.1.2.3 Recent developments 231 15.1.2.3.1 Deals 231 15.1.2.3.2 Other developments 231 15.1.2.4 MnM view 231 15.1.2.4.1 Key strengths/Right to win 231 15.1.2.4.2 Strategic choices 231 15.1.2.4.3 Weaknesses/Competitive threats 232 15.1.3 VEEVA SYSTEMS INC. 233 15.1.3.1 Business overview 233 15.1.3.2 Products offered 234 15.1.3.3 Recent developments 236 15.1.3.3.1 Product launches and approvals 236 15.1.3.3.2 Deals 236 15.1.3.4 MnM view 237 15.1.3.4.1 Key strengths/Right to win 237 15.1.3.4.2 Strategic choices 237 15.1.3.4.3 Weaknesses/Competitive threats 237 15.1.4 MASTERCONTROL SOLUTIONS, INC. 238 15.1.4.1 Business overview 238 15.1.4.2 Products offered 238 15.1.4.3 Recent developments 239 15.1.4.3.1 Deals 239 15.1.4.4 MnM view 240 15.1.4.4.1 Key strengths/Right to win 240 15.1.4.4.2 Strategic choices 240 15.1.4.4.3 Weaknesses/Competitive threats 240   15.1.5 DASSAULT SYSTÈMES 241 15.1.5.1 Business overview 241 15.1.5.2 Products offered 242 15.1.5.3 MnM view 243 15.1.5.3.1 Key strengths/Right to win 243 15.1.5.3.2 Strategic choices 243 15.1.5.3.3 Weaknesses/Competitive threats 243 15.1.6 QUALIO 244 15.1.6.1 Business overview 244 15.1.6.2 Products offered 244 15.1.7 HEXAGON AB 246 15.1.7.1 Business overview 246 15.1.7.2 Products offered 247 15.1.7.3 Recent developments 249 15.1.7.3.1 Product launches and approvals 249 15.1.7.3.2 Deals 249 15.1.8 ASSURX, INC. 250 15.1.8.1 Business overview 250 15.1.8.2 Products offered 250 15.1.8.3 Recent developments 252 15.1.8.3.1 Deals 252 15.1.9 QT9 SOFTWARE 253 15.1.9.1 Business overview 253 15.1.9.2 Products offered 253 15.1.9.3 Recent developments 254 15.1.9.3.1 Product launches and approvals 254 15.1.9.3.2 Deals 255 15.1.10 COMPLIANCEQUEST 256 15.1.10.1 Business overview 256 15.1.10.2 Products offered 256 15.1.10.3 Recent developments 257 15.1.10.3.1 Deals 257 15.1.11 IDEAGEN 258 15.1.11.1 Business overview 258 15.1.11.2 Products offered 258 15.1.11.3 Recent developments 259 15.1.11.3.1 Product launches and approvals 259 15.1.11.3.2 Deals 259   15.1.12 SOFTEXPERT 260 15.1.12.1 Business overview 260 15.1.12.2 Products offered 260 15.1.12.3 Recent developments 261 15.1.12.3.1 Deals 261 15.1.13 INSTEM 262 15.1.13.1 Business overview 262 15.1.13.2 Products offered 262 15.1.13.3 Recent developments 263 15.1.13.3.1 Deals 263 15.1.14 INTELEX TECHNOLOGIES 264 15.1.14.1 Business overview 264 15.1.14.2 Products offered 264 15.1.14.3 Recent developments 265 15.1.14.3.1 Product launches and approvals 265 15.1.14.3.2 Expansions 266 15.1.15 INTELLECT, INC 267 15.1.15.1 Business overview 267 15.1.15.2 Products offered 267 15.1.15.3 Recent developments 268 15.1.15.3.1 Product launches and approvals 268 15.1.16 AMPLELOGIC 269 15.1.16.1 Business overview 269 15.1.16.2 Products offered 269 15.1.16.3 Recent developments 271 15.1.16.3.1 Deals 271 15.2 OTHER PLAYERS 272 15.2.1 INSTANTGMP 272 15.2.2 SIMPLERQMS 273 15.2.3 DOT COMPLIANCE LTD. 273 15.2.4 SNIC SOLUTIONS 274 15.2.5 QUALITYZE 275 15.2.6 SCIGENIQ 275 15.2.7 KIVO, INC. 276 15.2.8 GMP SOFTWARE INDIA PVT. LTD. 276 15.2.9 VMT SOFT SOL PVT. LTD. 277   16 RESEARCH METHODOLOGY 278 16.1 RESEARCH DATA 278 16.1.1 SECONDARY DATA 279 16.1.1.1 Key data from secondary sources 280 16.1.2 PRIMARY DATA 280 16.1.2.1 Key data from primary sources 281 16.1.2.2 Key primary participants 282 16.1.2.3 Breakdown of primary interviews 282 16.1.2.4 Key industry insights 283 16.2 MARKET SIZE ESTIMATION 284 16.3 DATA TRIANGULATION 289 16.4 FACTOR ANALYSIS 290 16.5 RESEARCH ASSUMPTIONS 292 16.5.1 MARKET SIZING ASSUMPTIONS 292 16.5.2 STUDY ASSUMPTIONS 292 16.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT 293 16.6.1 RESEARCH LIMITATIONS 293 16.6.1.1 Methodology-related limitations 293 16.6.1.2 Scope-related limitations 293 16.6.2 RISK ASSESSMENT 293 17 APPENDIX 294 17.1 DISCUSSION GUIDE 294 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 298 17.3 CUSTOMIZATION OPTIONS 300 17.4 RELATED REPORTS 300 17.5 AUTHOR DETAILS 301
圖表清單 List of Tables & Figures
TABLE 1 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE: INCLUSIONS AND EXCLUSIONS 30 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2025 31 TABLE 3 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 43 TABLE 4 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS 54 TABLE 5 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET: ROLE OF COMPANIES IN ECOSYSTEM 60 TABLE 6 INDICATIVE PRICING ANALYSIS FOR PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE, BY KEY PLAYER, 2024 (USD) 61 TABLE 7 INDICATIVE PRICING ANALYSIS FOR PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE, BY PRICING PLANS, 2024 (USD) 62 TABLE 8 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 63 TABLE 9 CASE STUDY 1: IMPROVED COMPLIANCE & EFFICIENCY WITH CONFIGURABLE EQMS 65 TABLE 10 CASE STUDY 2: STREAMLINED CHANGE CONTROL & DOCUMENT MANAGEMENT WITH TRACKWISE DIGITAL 66 TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 67 TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, JANUARY 2015–NOVEMBER 2025 73 TABLE 13 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: LIST OF PATENTS/PATENT APPLICATIONS 74 TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 19 REGULATORY SCENARIO OF NORTH AMERICA 88 TABLE 20 REGULATORY SCENARIO OF EUROPE 88 TABLE 21 REGULATORY SCENARIO OF ASIA PACIFIC 89 TABLE 22 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 90 TABLE 23 REGULATORY SCENARIO OF LATIN AMERICA 90 TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 92 TABLE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS 92 TABLE 26 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: UNMET NEEDS 93 TABLE 27 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 95 TABLE 28 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CLINICAL TRIALS, BY REGION, 2023–2030 (USD MILLION) 96 TABLE 29 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023–2030 (USD MILLION) 97 TABLE 30 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR MANUFACTURING/PRODUCTION, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 31 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR QUALITY ASSURANCE/QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 32 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR DISTRIBUTION & SUPPLY CHAIN, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 33 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR COMMERCIALIZATION, MARKETING, AND SALES, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 34 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR POST-MARKET SURVEILLANCE, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 35 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR OTHER PROCESSES, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 36 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 105 TABLE 37 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR DOCUMENT & ESOP, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 38 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CAPA (CORRECTIVE & PREVENTIVE ACTION) MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 39 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR AUDIT & INSPECTION MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 40 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR TRAINING MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 41 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR REGULATORY & COMPLIANCE MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 42 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR SUPPLIER QUALITY MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 43 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR RISK MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 44 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CHANGE CONTROL MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 45 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 46 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 116 TABLE 47 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR LARGE ENTERPRISES, REGION, 2023–2030 (USD MILLION) 117 TABLE 48 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR SMALL & MEDIUM ENTERPRISES, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 49 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 120 TABLE 50 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 51 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 52 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 53 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 54 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 55 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 56 NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 57 NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 130 TABLE 58 NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 130 TABLE 59 NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 131 TABLE 60 NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 131 TABLE 61 US: MAJOR COMPANIES IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET 132 TABLE 62 US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 132 TABLE 63 US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 133 TABLE 64 US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 133 TABLE 65 US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 134 TABLE 66 CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 135 TABLE 67 CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 135 TABLE 68 CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 136 TABLE 69 CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 136 TABLE 70 EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 71 EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 138 TABLE 72 EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 138 TABLE 73 EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 139 TABLE 74 EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 139 TABLE 75 GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 140 TABLE 76 GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 141 TABLE 77 GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 141 TABLE 78 GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 142 TABLE 79 UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 143 TABLE 80 UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 143 TABLE 81 UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 144 TABLE 82 UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 144 TABLE 83 FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 145 TABLE 84 FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 146 TABLE 85 FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 146 TABLE 86 FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 147 TABLE 87 ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 148 TABLE 88 ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 148 TABLE 89 ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 149 TABLE 90 ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 149 TABLE 91 SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 150 TABLE 92 SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 151 TABLE 93 SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 151 TABLE 94 SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 152 TABLE 95 REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 153 TABLE 96 REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 153 TABLE 97 REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 154 TABLE 98 REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 154 TABLE 99 ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 100 ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 157 TABLE 101 ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 157 TABLE 102 ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 158 TABLE 103 ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 104 CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 159 TABLE 105 CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 160 TABLE 106 CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 160 TABLE 107 CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 161 TABLE 108 JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 162 TABLE 109 JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 162 TABLE 110 JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 163 TABLE 111 JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 163 TABLE 112 INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 164 TABLE 113 INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 165 TABLE 114 INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION) 165 TABLE 115 INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 166 TABLE 116 AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 167 TABLE 117 AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 167 TABLE 118 AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 168 TABLE 119 AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 120 SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 169 TABLE 121 SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 170 TABLE 122 SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 170 TABLE 123 SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER 2023–2030 (USD MILLION) 171 TABLE 124 REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 172 TABLE 125 REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 172 TABLE 126 REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 173 TABLE 127 REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER 2023–2030 (USD MILLION) 173 TABLE 128 LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 129 LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 175 TABLE 130 LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 175 TABLE 131 LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 176 TABLE 132 LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 176 TABLE 133 BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 177 TABLE 134 BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 178 TABLE 135 BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 178 TABLE 136 BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 179 TABLE 137 MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 180 TABLE 138 MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 180 TABLE 139 MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION) 181 TABLE 140 MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 181 TABLE 141 REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 182 TABLE 142 REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030(USD MILLION) 182 TABLE 143 REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION) 183 TABLE 144 REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 183 TABLE 145 MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 146 MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 185 TABLE 147 MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 185 TABLE 148 MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 186 TABLE 149 MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 150 GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 151 GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 187 TABLE 152 GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 188 TABLE 153 GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 188 TABLE 154 GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 189 TABLE 155 SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 190 TABLE 156 SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190 TABLE 157 SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 191 TABLE 158 SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 191 TABLE 159 UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 192 TABLE 160 UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 193 TABLE 161 UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 193 TABLE 162 UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 194 TABLE 163 REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 195 TABLE 164 REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195 TABLE 165 REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION) 196 TABLE 166 REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 196 TABLE 167 SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 197 TABLE 168 SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198 TABLE 169 SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 198 TABLE 170 SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER 2023–2030 (USD MILLION) 199 TABLE 171 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION) 200 TABLE 172 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 200 TABLE 173 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION) 201 TABLE 174 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 175 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, JANUARY 2022–OCTOBER 2025 203 TABLE 176 PHARMACEUTICAL QUALITY MANAGEMENT MARKET: DEGREE OF COMPETITION 206 TABLE 177 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REGION FOOTPRINT 212 TABLE 178 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PROCESS FOOTPRINT 213 TABLE 179 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: APPLICATION FOOTPRINT 214 TABLE 180 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: ENTERPRISE SIZE FOOTPRINT 215 TABLE 181 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: END-USER FOOTPRINT 216 TABLE 182 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DETAILED LIST OF KEY STARTUPS/SMES 219 TABLE 183 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 220 TABLE 184 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 222 TABLE 185 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DEALS, JANUARY 2022–OCTOBER 2025 223 TABLE 186 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: EXPANSIONS, JANUARY 2022–OCTOBER 2025 224 TABLE 187 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025 224 TABLE 188 HONEYWELL INTERNATIONAL INC.: COMPANY OVERVIEW 225 TABLE 189 HONEYWELL INTERNATIONAL INC.: PRODUCTS OFFERED 226 TABLE 190 HONEYWELL INTERNATIONAL INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 227 TABLE 191 HONEYWELL INTERNATIONAL INC.: JANUARY 2022–OCTOBER 2025 228 TABLE 192 IQVIA: COMPANY OVERVIEW 229 TABLE 193 IQVIA: PRODUCTS OFFERED 230 TABLE 194 IQVIA: DEALS, JANUARY 2022–OCTOBER 2025 231 TABLE 195 IQVIA: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025 231 TABLE 196 VEEVA SYSTEMS INC.: COMPANY OVERVIEW 233 TABLE 197 VEEVA SYSTEMS INC.: PRODUCTS OFFERED 234 TABLE 198 VEEVA SYSTEMS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 236 TABLE 199 VEEVA SYSTEMS INC.: DEALS, JANUARY 2022–OCTOBER 2025 236 TABLE 200 MASTERCONTROL SOLUTIONS, INC.: COMPANY OVERVIEW 238 TABLE 201 MASTERCONTROL SOLUTIONS, INC.: PRODUCTS OFFERED 238 TABLE 202 MASTERCONTROL SOLUTIONS, INC.: DEALS, JANUARY 2022–OCTOBER 2025 239 TABLE 203 DASSAULT SYSTÈMES: COMPANY OVERVIEW 241 TABLE 204 DASSAULT SYSTÈMES: PRODUCTS OFFERED 242 TABLE 205 QUALIO: COMPANY OVERVIEW 244 TABLE 206 QUALIO: PRODUCTS OFFERED 244 TABLE 207 HEXAGON AB: COMPANY OVERVIEW 246 TABLE 208 HEXAGON AB: PRODUCTS OFFERED 247 TABLE 209 HEXAGON AB: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 249 TABLE 210 HEXAGON AB.: DEALS, JANUARY 2022–OCTOBER 2025 249 TABLE 211 ASSURX, INC.: COMPANY OVERVIEW 250 TABLE 212 ASSURX, INC.: PRODUCTS OFFERED 250 TABLE 213 ASSURX, INC.: DEALS, JANUARY 2022–OCTOBER 2025 252 TABLE 214 QT9 SOFTWARE: COMPANY OVERVIEW 253 TABLE 215 QT9 SOFTWARE: PRODUCTS OFFERED 253 TABLE 216 QT9 SOFTWARE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 254 TABLE 217 QT9 SOFTWARE: DEALS, JANUARY 2022–OCTOBER 2025 255 TABLE 218 COMPLIANCEQUEST: COMPANY OVERVIEW 256 TABLE 219 COMPLIANCEQUEST: PRODUCTS OFFERED 256 TABLE 220 COMPLIANCEQUEST: DEALS, JANUARY 2022–OCTOBER 2025 257 TABLE 221 IDEAGEN: COMPANY OVERVIEW 258 TABLE 222 IDEAGEN: PRODUCTS OFFERED 258 TABLE 223 IDEAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 259 TABLE 224 IDEAGEN: DEALS, JANUARY 2022–OCTOBER 2025 259 TABLE 225 SOFTEXPERT: COMPANY OVERVIEW 260 TABLE 226 SOFTEXPERT: PRODUCTS OFFERED 260 TABLE 227 SOFTEXPERT: DEALS, JANUARY 2022–OCTOBER 2025 261 TABLE 228 INSTEM: COMPANY OVERVIEW 262 TABLE 229 INSTEM: PRODUCTS OFFERED 262 TABLE 230 INSTEM: DEALS, JANUARY 2022–OCTOBER 2025 263 TABLE 231 INTELEX TECHNOLOGIES: COMPANY OVERVIEW 264 TABLE 232 INTELEX TECHNOLOGIES: PRODUCTS OFFERED 264 TABLE 233 INTELEX TECHNOLOGIES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– OCTOBER 2025 265 TABLE 234 INTELEX TECHNOLOGIES: EXPANSIONS, JANUARY 2022–OCTOBER 2024 266 TABLE 235 INTELLECT, INC.: COMPANY OVERVIEW 267 TABLE 236 INTELLECT, INC.: PRODUCTS OFFERED 267 TABLE 237 INTELLECT, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 268 TABLE 238 AMPLELOGIC: COMPANY OVERVIEW 269 TABLE 239 AMPLELOGIC: PRODUCTS OFFERED 269 TABLE 240 AMPLELOGIC: DEALS, JANUARY 2022–OCTOBER 2025 271 TABLE 241 INSTANTGMP: COMPANY OVERVIEW 272 TABLE 242 SIMPLERQMS: COMPANY OVERVIEW 273 TABLE 243 DOT COMPLIANCE LTD.: COMPANY OVERVIEW 273 TABLE 244 SNIC SOLUTIONS: COMPANY OVERVIEW 274 TABLE 245 QUALITYZE: COMPANY OVERVIEW 275 TABLE 246 SCIGENIQ: COMPANY OVERVIEW 275 TABLE 247 KIVO, INC.: COMPANY OVERVIEW 276 TABLE 248 GMP SOFTWARE INDIA PVT. LTD.: COMPANY OVERVIEW 276 TABLE 249 VMT SOFT SOL PVT. LTD.: COMPANY OVERVIEW 277 TABLE 250 FACTOR ANALYSIS 290 TABLE 251 MARKET SIZING ASSUMPTIONS 292 TABLE 252 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: RISK ASSESSMENT 293 FIGURE 1 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SEGMENTATION AND REGIONAL SCOPE 29 FIGURE 2 MARKET SCENARIO 33 FIGURE 3 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2023–2030 34 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2023–2030 34 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET 35 FIGURE 6 HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2025–2030 36 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MARKET DURING FORECAST PERIOD 37 FIGURE 8 INCREASING ENFORCEMENT OF GLOBAL QUALITY STANDARDS AND REGULATORY UPGRADES TO DRIVE MARKET 38 FIGURE 9 LARGE ENTERPRISES AND US LED NORTH AMERICAN MARKET IN 2024 39 FIGURE 10 CANADA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 40 FIGURE 11 EMERGING MARKETS TO HAVE HIGHER GROWTH DURING FORECAST PERIOD 41 FIGURE 12 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42 FIGURE 13 US MEDIAN HEALTHCARE DATA BREACH, 2009–2024 47 FIGURE 14 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS 53 FIGURE 15 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET: VALUE CHAIN ANALYSIS 57 FIGURE 16 NEW REVENUE POCKETS AND REVENUE SHIFT IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET 64 FIGURE 17 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: INVESTMENT AND FUNDING SCENARIO 65 FIGURE 18 JURISDICTION ANALYSIS, JANUARY 2015–NOVEMBER 2025 72 FIGURE 19 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PATENT ANALYSIS, JANUARY 2015–NOVEMBER 2024 74 FIGURE 20 MARKET POTENTIAL OF AI/GEN AI ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET ACROSS INDUSTRIES 78 FIGURE 21 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 81 FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 91 FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 92 FIGURE 24 NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SNAPSHOT 129 FIGURE 25 ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SNAPSHOT 156 FIGURE 26 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 (USD MILLION) 205 FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, 2024 206 FIGURE 28 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: SOFTWARE COMPARISON 208 FIGURE 29 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 210 FIGURE 30 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY FOOTPRINT 211 FIGURE 31 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 218 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 221 FIGURE 33 EV/EBITDA OF KEY VENDORS 221 FIGURE 34 HONEYWELL INTERNATIONAL INC.: COMPANY SNAPSHOT (2024) 226 FIGURE 35 IQVIA: COMPANY SNAPSHOT (2024) 230 FIGURE 36 VEEVA SYSTEMS INC.: COMPANY SNAPSHOT (2024) 234 FIGURE 37 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2024) 242 FIGURE 38 HEXAGON AB: COMPANY SNAPSHOT (2024) 247 FIGURE 39 RESEARCH DESIGN 278 FIGURE 40 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 282 FIGURE 41 SUPPLY-SIDE MARKET ESTIMATION 285 FIGURE 42 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REVENUE ESTIMATION APPROACH 285 FIGURE 43 BOTTOM-UP APPROACH: END-USER SPENDING ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE 287 FIGURE 44 TOP-DOWN APPROACH 288 FIGURE 45 DATA TRIANGULATION 289 FIGURE 46 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2025–2030 291 FIGURE 47 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 291 FIGURE 1 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SEGMENTATION AND REGIONAL SCOPE 29 FIGURE 2 MARKET SCENARIO 33 FIGURE 3 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2023–2030 34 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2023–2030 34 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET 35 FIGURE 6 HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2025–2030 36 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MARKET DURING FORECAST PERIOD 37 FIGURE 8 INCREASING ENFORCEMENT OF GLOBAL QUALITY STANDARDS AND REGULATORY UPGRADES TO DRIVE MARKET 38 FIGURE 9 LARGE ENTERPRISES AND US LED NORTH AMERICAN MARKET IN 2024 39 FIGURE 10 CANADA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 40 FIGURE 11 EMERGING MARKETS TO HAVE HIGHER GROWTH DURING FORECAST PERIOD 41 FIGURE 12 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42 FIGURE 13 US MEDIAN HEALTHCARE DATA BREACH, 2009–2024 47 FIGURE 14 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS 53 FIGURE 15 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET: VALUE CHAIN ANALYSIS 57 FIGURE 16 NEW REVENUE POCKETS AND REVENUE SHIFT IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET 64 FIGURE 17 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: INVESTMENT AND FUNDING SCENARIO 65 FIGURE 18 JURISDICTION ANALYSIS, JANUARY 2015–NOVEMBER 2025 72 FIGURE 19 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PATENT ANALYSIS, JANUARY 2015–NOVEMBER 2024 74 FIGURE 20 MARKET POTENTIAL OF AI/GEN AI ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET ACROSS INDUSTRIES 78 FIGURE 21 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 81 FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 91 FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 92 FIGURE 24 NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SNAPSHOT 129 FIGURE 25 ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SNAPSHOT 156 FIGURE 26 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 (USD MILLION) 205 FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, 2024 206 FIGURE 28 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: SOFTWARE COMPARISON 208 FIGURE 29 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 210 FIGURE 30 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY FOOTPRINT 211 FIGURE 31 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 218 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 221 FIGURE 33 EV/EBITDA OF KEY VENDORS 221 FIGURE 34 HONEYWELL INTERNATIONAL INC.: COMPANY SNAPSHOT (2024) 226 FIGURE 35 IQVIA: COMPANY SNAPSHOT (2024) 230 FIGURE 36 VEEVA SYSTEMS INC.: COMPANY SNAPSHOT (2024) 234 FIGURE 37 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2024) 242 FIGURE 38 HEXAGON AB: COMPANY SNAPSHOT (2024) 247 FIGURE 39 RESEARCH DESIGN 278 FIGURE 40 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 282 FIGURE 41 SUPPLY-SIDE MARKET ESTIMATION 285 FIGURE 42 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REVENUE ESTIMATION APPROACH 285 FIGURE 43 BOTTOM-UP APPROACH: END-USER SPENDING ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE 287 FIGURE 44 TOP-DOWN APPROACH 288 FIGURE 45 DATA TRIANGULATION 289 FIGURE 46 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2025–2030 291 FIGURE 47 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 291

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們